Erlotinib (Tarceva) and gefitinib (Iressa) are among the first targeted drugs approved to treat lung cancer. These and other similar drugs given as pills target epidermal growth factor receptor (EGFR), a protein that, when overreactive, makes cancer cells grow and divide. These mutations are more common in people with lung cancer who are female or who have never smoked.
These drugs have had success in prolonging the time that the cancer does not worsen, both alone and in combination with chemotherapy and immunotherapy. If the cancer does develop resistance to the drug, alternative treatments are then considered.
Employing the immune system is now a viable treatment option for many more people with advanced-stage lung cancer.
The Outlook for Immunotherapy Treatment
Immunotherapy Has Changed The Game For Lung Cancer
A Much More Effective Alternative to Chemotherapy
Is Immunotherapy Right for My Lung Cancer?
What Do Checkpoint Inhibitors Do For Cancer?
The Importance Of Genetics In Late Stage Lung Cancers
Targeted Therapy for Lung Cancer
Getting Genetic Sequencing
How Checkpoint Inhibitors Work in Lung Cancer
How to Determine If Targeted Therapy Is Right for You
Combining Immunotherapy Drugs in Lung Cancer Clinical Trials
Immunotherapy for Advanced Lung Cancer
Why I'd Choose a Clinical Trial For Myself
Clinical Trials and What Statistics Really Mean
When Should I Consider Clinical Trials?
The Father of Immunotherapy Recommends Multiple Opinions